VXRT [NASD]
Vaxart, Inc.
Index- P/E- EPS (ttm)-0.64 Insider Own0.30% Shs Outstand125.80M Perf Week11.38%
Market Cap406.97M Forward P/E- EPS next Y-0.73 Insider Trans-1.09% Shs Float125.35M Perf Month-7.23%
Income-79.60M PEG- EPS next Q-0.19 Inst Own35.70% Short Float18.62% Perf Quarter-21.68%
Sales0.50M P/S813.94 EPS this Y-59.00% Inst Trans3.76% Short Ratio8.83 Perf Half Y-47.31%
Book/sh1.32 P/B2.82 EPS next Y3.40% ROA-35.70% Target Price11.60 Perf Year-44.48%
Cash/sh1.35 P/C2.76 EPS next 5Y- ROE-42.00% 52W Range2.49 - 10.33 Perf YTD-40.67%
Dividend- P/FCF- EPS past 5Y41.40% ROI-36.80% 52W High-63.99% Beta0.77
Dividend %- Quick Ratio14.00 Sales past 5Y-36.90% Gross Margin- 52W Low49.40% ATR0.36
Employees110 Current Ratio14.00 Sales Q/Q-80.00% Oper. Margin- RSI (14)50.15 Volatility10.55% 10.67%
OptionableYes Debt/Eq0.00 EPS Q/Q-43.90% Profit Margin- Rel Volume1.40 Prev Close3.52
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.64M Price3.72
Recom2.00 SMA206.51% SMA50-13.52% SMA200-39.54% Volume3,701,128 Change5.68%
Dec-29-21Resumed Jefferies Buy $13 → $12
Nov-02-21Initiated Cantor Fitzgerald Overweight $15
Jun-29-21Downgrade B. Riley Securities Buy → Neutral $13 → $9
Jun-24-21Initiated Jefferies Buy $13
Jun-11-21Initiated Piper Sandler Overweight $18
Aug-12-20Reiterated H.C. Wainwright Buy $7 → $17
Jul-13-20Initiated B. Riley FBR Buy $22
May-20-22 03:33PM  
May-19-22 08:30AM  
May-18-22 05:51AM  
May-16-22 06:00AM  
May-13-22 04:17PM  
May-09-22 05:46PM  
May-04-22 02:25PM  
Apr-27-22 06:30AM  
Apr-14-22 08:30AM  
06:00AM  
Apr-07-22 05:51AM  
Apr-06-22 05:21AM  
Mar-29-22 10:12AM  
Mar-26-22 11:15AM  
06:55AM  
Mar-24-22 11:37AM  
Mar-09-22 06:30AM  
Feb-24-22 07:10PM  
04:05PM  
08:30AM  
Feb-23-22 06:15AM  
Feb-17-22 03:02PM  
Feb-16-22 10:58AM  
09:54AM  
Feb-15-22 05:55PM  
Feb-14-22 08:00AM  
Feb-11-22 11:23AM  
Feb-09-22 01:23PM  
Feb-07-22 12:00PM  
Jan-29-22 06:55AM  
05:51AM  
Jan-27-22 06:33AM  
05:36AM  
Jan-12-22 11:10AM  
06:15AM  
Jan-10-22 07:55AM  
06:00AM  
Jan-04-22 08:00AM  
Dec-30-21 02:59PM  
Dec-21-21 10:37AM  
Dec-20-21 06:23AM  
Dec-16-21 09:05AM  
08:00AM  
Dec-15-21 06:00AM  
Dec-14-21 05:51AM  
Dec-06-21 01:45PM  
Dec-03-21 03:18PM  
Dec-01-21 03:14PM  
08:00AM  
Nov-23-21 08:00AM  
Nov-21-21 06:00AM  
Nov-18-21 04:02PM  
Nov-16-21 08:00AM  
Nov-11-21 04:01PM  
Nov-05-21 06:25AM  
Nov-04-21 05:25PM  
04:01PM  
03:01PM  
Nov-03-21 05:51AM  
Oct-26-21 08:00AM  
Oct-19-21 05:00AM  
Oct-16-21 11:30AM  
Oct-13-21 06:54PM  
Oct-10-21 06:00AM  
Oct-08-21 09:57AM  
07:57AM  
07:34AM  
04:45AM  
Oct-07-21 07:16PM  
04:57PM  
04:13PM  
10:00AM  
07:29AM  
Oct-06-21 02:20PM  
08:00AM  
07:29AM  
Oct-04-21 08:40AM  
Oct-02-21 10:56AM  
Oct-01-21 12:41PM  
Sep-30-21 05:51AM  
Sep-27-21 08:00AM  
Sep-22-21 04:05PM  
Sep-21-21 04:15PM  
Sep-20-21 08:00AM  
Sep-16-21 05:51AM  
Sep-07-21 04:20PM  
Aug-27-21 06:00AM  
Aug-23-21 02:45PM  
09:00AM  
Aug-19-21 04:02PM  
Aug-11-21 08:54AM  
Aug-09-21 01:40PM  
Aug-05-21 06:35PM  
04:02PM  
Aug-02-21 02:41PM  
08:27AM  
08:00AM  
06:00AM  
Jul-29-21 03:05PM  
08:22AM  
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tucker SeanSVP, Chief Scientific OfficerApr 22Option Exercise0.7740,00030,800127,631Apr 25 04:40 PM
Echerd MargaretSVP, Principal Accntng OfficerNov 30Option Exercise1.583,6025,7043,602Dec 01 04:05 PM
Echerd MargaretSVP, Principal Accntng OfficerNov 30Sale8.003,60228,8160Dec 01 04:05 PM
Echerd MargaretSVP, Principal Accntng OfficerSep 10Option Exercise1.591,8012,8561,801Sep 13 07:29 PM
Echerd MargaretSVP, Principal Accntng OfficerSep 10Sale9.101,80116,3890Sep 13 07:29 PM
Echerd MargaretSVP, Principal Accntng OfficerAug 10Option Exercise1.581,8012,8521,801Aug 11 06:52 PM
Tucker SeanSVP, Chief Scientific OfficerAug 10Sale10.205,82859,44651,465Aug 11 06:53 PM
Tucker SeanSVP, Chief Scientific OfficerAug 10Sale10.204,17242,55443,881Aug 11 06:53 PM
Echerd MargaretSVP, Principal Accntng OfficerAug 10Sale10.001,80118,0100Aug 11 06:52 PM
Echerd MargaretSVP, Principal Accntng OfficerJul 19Option Exercise1.581,8002,8511,800Jul 21 04:32 PM
Echerd MargaretSVP, Principal Accntng OfficerJul 19Sale8.001,80014,4000Jul 21 04:32 PM
Finney Michael J.DirectorJun 18Option Exercise0.6821,70014,756474,272Jun 21 04:44 PM
Yedid Robert A.DirectorJun 11Option Exercise0.3118,2405,65418,240Jun 14 04:17 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 11Option Exercise1.591,8022,8571,802Jun 14 04:16 PM
Yedid Robert A.DirectorJun 11Sale8.6110,00086,1098,240Jun 14 04:17 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 11Sale8.001,80214,4160Jun 14 04:16 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 09Option Exercise1.9147,55590,88347,555Jun 11 04:17 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 09Sale8.0047,555380,4400Jun 11 04:17 PM